CA3204599A1 - 5ht agonists for treating disorders - Google Patents

5ht agonists for treating disorders

Info

Publication number
CA3204599A1
CA3204599A1 CA3204599A CA3204599A CA3204599A1 CA 3204599 A1 CA3204599 A1 CA 3204599A1 CA 3204599 A CA3204599 A CA 3204599A CA 3204599 A CA3204599 A CA 3204599A CA 3204599 A1 CA3204599 A1 CA 3204599A1
Authority
CA
Canada
Prior art keywords
receptor agonist
receptor
pharmaceutically acceptable
epilepsy
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204599A
Other languages
English (en)
French (fr)
Inventor
Scott C. Baraban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3204599A1 publication Critical patent/CA3204599A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3204599A 2015-02-25 2016-02-24 5ht agonists for treating disorders Pending CA3204599A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562120726P 2015-02-25 2015-02-25
US62/120,726 2015-02-25
CA2977135A CA2977135C (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2977135A Division CA2977135C (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders

Publications (1)

Publication Number Publication Date
CA3204599A1 true CA3204599A1 (en) 2016-09-01

Family

ID=56789223

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3204599A Pending CA3204599A1 (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders
CA2977135A Active CA2977135C (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2977135A Active CA2977135C (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders

Country Status (21)

Country Link
US (5) US10874643B2 (enExample)
EP (4) EP3632434A1 (enExample)
JP (5) JP6884703B2 (enExample)
KR (3) KR20220048045A (enExample)
CN (2) CN107530326B (enExample)
AU (3) AU2016222804C1 (enExample)
BR (1) BR112017018297B1 (enExample)
CA (2) CA3204599A1 (enExample)
CY (1) CY1125360T1 (enExample)
DK (1) DK3261640T3 (enExample)
EA (2) EA201992474A3 (enExample)
ES (2) ES2920886T3 (enExample)
HR (1) HRP20220822T1 (enExample)
HU (1) HUE059559T2 (enExample)
LT (1) LT3261640T (enExample)
PL (1) PL3261640T3 (enExample)
PT (1) PT3261640T (enExample)
RS (1) RS63426B1 (enExample)
SI (1) SI3261640T1 (enExample)
SM (1) SMT202200276T1 (enExample)
WO (1) WO2016138138A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
SI3261640T1 (sl) 2015-02-25 2022-10-28 The Regents Of The University Of California 5HT agonisti za zdravljenje epilepsijskih motenj
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
EP3800177B1 (en) 2015-12-22 2025-01-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2020018839A1 (en) 2018-07-18 2020-01-23 The Regents Of The University Of California Compounds and methods for synergistic activation of m channels
MX2021000987A (es) * 2018-07-27 2021-06-15 Xenon Pharmaceuticals Inc Metodo para tratar la epilepsia.
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
CN114007692A (zh) * 2019-05-29 2022-02-01 加利福尼亚大学董事会 治疗癫痫的方法和组合物
EP3791873A1 (en) 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
BR112022007648A2 (pt) * 2019-10-23 2022-10-11 Neurocycle Therapeutics Inc Tratamento de condições epilépticas com moduladores do receptor gabaa
SI4048249T1 (sl) * 2019-10-23 2026-04-30 Maplight Therapeutics, Inc. Postopki zdravljenja simptomov motnje avtističnega spektra
KR20210054684A (ko) 2019-11-06 2021-05-14 동국대학교 경주캠퍼스 산학협력단 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CN114828889B (zh) * 2019-12-06 2025-02-14 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
KR102476771B1 (ko) * 2020-05-08 2022-12-13 광운대학교 산학협력단 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
MX2023011240A (es) * 2021-03-25 2024-01-12 Maplight Therapeutics Inc Composiciones farmaceuticas que comprenden zolmitriptan.
CA3221934A1 (en) * 2021-06-01 2022-12-08 Arena Pharmaceuticals, Inc. Methods of treatment
US12599611B2 (en) * 2021-06-10 2026-04-14 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
JP7856338B2 (ja) * 2021-07-30 2026-05-11 エピジェニクス セラピューティクス インコーポレーテッド クレミゾール製剤
WO2023107965A1 (en) * 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc)
US11974992B2 (en) 2022-01-26 2024-05-07 Neurolixis Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023212244A1 (en) * 2022-04-27 2023-11-02 Tessellate Therapeutics, Inc. Methods of treating 5ht2a receptor-mediated conditions
IL315086A (en) 2022-06-09 2024-10-01 Diamond Therapeutics Inc Amorphous (A-polymorphic) psilocybin
US20240174594A1 (en) * 2022-11-30 2024-05-30 Mind Medicine, Inc. 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action
CN119564685B (zh) * 2024-12-16 2026-02-06 中国人民解放军军事科学院军事医学研究院 Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7582428B2 (en) 2003-08-22 2009-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
US20050215589A1 (en) * 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008036586A2 (en) 2006-09-20 2008-03-27 Waters Investments Limited Apparatus and methods of fluid chromatography
EP2134556B1 (en) 2007-04-06 2012-07-18 Koninklijke Philips Electronics N.V. Air pollution sensor system
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
US20110009351A1 (en) 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
TW200927102A (en) * 2007-09-18 2009-07-01 Univ Stanford Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
KR100925176B1 (ko) 2007-09-21 2009-11-05 한국전자통신연구원 지리 정보를 이용한 네트워크 상태 표시장치 및 방법
NZ594937A (en) * 2008-02-19 2013-03-28 Adolor Corp Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
CA2719373A1 (en) 2008-04-16 2009-10-22 Arena Pharmaceuticals, Inc. Processes useful for the synthesis of (r)-1-{2-[4'-(3-methoxypropane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine
AU2009246316B2 (en) 2008-05-16 2014-06-19 Nono Inc. Treatment for epilepsy
US20110217265A1 (en) 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
JP2012520885A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
JP5656980B2 (ja) 2009-05-13 2015-01-21 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー含有の置換芳香族トリアジン化合物
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
WO2014123909A1 (en) * 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
PT3035926T (pt) 2013-08-19 2020-09-01 Univ California Compostos e métodos para tratar um distúrbio epiléptico
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN104936947B (zh) * 2013-12-27 2017-03-08 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
SI3261640T1 (sl) 2015-02-25 2022-10-28 The Regents Of The University Of California 5HT agonisti za zdravljenje epilepsijskih motenj
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
US20200147048A1 (en) 2020-05-14
EP3632434A1 (en) 2020-04-08
WO2016138138A1 (en) 2016-09-01
US11648237B2 (en) 2023-05-16
PL3261640T3 (pl) 2022-10-31
AU2022203274B2 (en) 2024-08-15
RS63426B1 (sr) 2022-08-31
SI3261640T1 (sl) 2022-10-28
US12447144B2 (en) 2025-10-21
US20210154171A1 (en) 2021-05-27
EP4043016A1 (en) 2022-08-17
CN107530326B (zh) 2021-09-21
KR20220048045A (ko) 2022-04-19
US20260083706A1 (en) 2026-03-26
JP6884703B2 (ja) 2021-06-09
JP2022116307A (ja) 2022-08-09
JP2024009839A (ja) 2024-01-23
CN107530326A (zh) 2018-01-02
JP7846506B2 (ja) 2026-04-15
US20180028499A1 (en) 2018-02-01
AU2021204261A1 (en) 2021-07-29
PT3261640T (pt) 2022-07-06
EP4696377A3 (en) 2026-04-29
AU2016222804B2 (en) 2021-07-15
ES2920886T3 (es) 2022-08-11
EP4696377A2 (en) 2026-02-18
KR20230152844A (ko) 2023-11-03
KR20170118870A (ko) 2017-10-25
AU2022203274A1 (en) 2022-06-16
CA2977135C (en) 2023-08-22
EA201992474A3 (ru) 2020-05-31
CY1125360T1 (el) 2025-05-09
AU2021204261B2 (en) 2023-08-10
AU2016222804A1 (en) 2017-08-31
KR102385665B1 (ko) 2022-04-14
CN113546174A (zh) 2021-10-26
BR112017018297B1 (pt) 2023-12-05
HRP20220822T1 (hr) 2022-10-28
ES3060954T3 (en) 2026-03-30
EP3261640A4 (en) 2018-12-19
AU2016222804C1 (en) 2021-10-14
EP3261640A1 (en) 2018-01-03
LT3261640T (lt) 2022-07-11
BR112017018297A2 (pt) 2018-04-17
EP4043016B1 (en) 2025-10-29
DK3261640T3 (da) 2022-07-11
JP2018506555A (ja) 2018-03-08
SMT202200276T1 (it) 2022-09-14
US20230346750A1 (en) 2023-11-02
CA2977135A1 (en) 2016-09-01
EA201791882A1 (ru) 2018-02-28
EP3261640B1 (en) 2022-04-06
EA201992474A2 (ru) 2020-02-28
US10874643B2 (en) 2020-12-29
JP2020143087A (ja) 2020-09-10
JP2021185148A (ja) 2021-12-09
HUE059559T2 (hu) 2022-12-28

Similar Documents

Publication Publication Date Title
AU2022203274B2 (en) 5HT agonists for treating disorders
US12419866B2 (en) Compounds and methods for treating an epileptic disorder
HK40079848A (en) The 5ht agonist clemizole for use in treating epilepsy disorders
HK40062533A (zh) 用於治疗病症的5ht激动剂
HK40016257A (en) Compounds and methods for treating an epileptic disorder
HK1225984B (en) Compounds and methods for treating an epileptic disorder

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230921

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241022

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250227

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250529

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250619

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250911